Overview
Lymphatic filariasis, primarily caused by Wuchereria bancrofti, is a mosquito-borne parasitic disease leading to significant morbidity through lymphatic system damage and social impacts 1.Diagnosis
Preferred Diagnostic Tests: Polymerase Chain Reaction (PCR) using sputum samples shows high sensitivity (97.5%) and specificity (92.4%) for detecting Wuchereria bancrofti infections 3.
Alternative Methods: Microfilaria counts and immunochromatographic tests (ICT) are also used but with varying sensitivity compared to PCR 3.
Psychosocial Considerations: Anxiety and illness anxiety disorder related to filariasis can complicate diagnosis and management, necessitating psychological support 2.Management
Mass Drug Administration (MDA): Diethylcarbamazine (DEC) and albendazole are commonly used in MDA programs 4.
Adverse Effects Monitoring: Regular pharmacovigilance through consumer feedback is essential to monitor adverse drug reactions, which are generally mild (e.g., drowsiness, headache, gastrointestinal symptoms) 4.
Vaccine Development: Research focuses on immunoinformatics approaches to design multiepitope vaccines targeting specific filarial proteins, though these are still in development stages 1.Special Populations
Adverse Reactions in Specific Groups: No specific data provided for pregnancy, pediatrics, or elderly populations; adverse reactions noted in general population are mild and do not typically require hospitalization 4.
Psychosocial Impact: Particular attention to mental health support is advised in populations where filariasis is prevalent due to potential anxiety disorders 2.Key Recommendations
Utilize PCR assays with sputum samples for accurate diagnosis of Wuchereria bancrofti infections due to high sensitivity and specificity (Evidence: Strong 3).
Implement mass drug administration programs using DEC and albendazole, coupled with pharmacovigilance to monitor adverse reactions (Evidence: Moderate 4).
Consider psychological support for patients exhibiting illness anxiety disorder related to filariasis (Evidence: Weak 2).References
1 Parvin R, Habib Ullah Masum M, Ferdous J, Mahdeen AA, Shafiqul Islam Khan M. Designing of a chimeric multiepitope vaccine against bancroftian lymphatic filariasis through immunoinformatics approaches. PloS one 2024. link
2 Karia S, Shah N, Sonavane S, De Sousa A. Illness anxiety disorder related to filariasis: a case report. Journal of the Egyptian Society of Parasitology 2015. link
3 Kagai JM, Mpoke S, Muli F, Hamburger J, Kenya EU. Molecular technique utilising sputum for detecting Wuchereria bancrofti infections in Malindi, Kenya. East African medical journal 2008. link
4 Gunawardena S, Sri Ranganathan S, Fernandopulle R. Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka. Tropical medicine & international health : TM & IH 2008. link
5 Rathaur S, Robertson BD, Selkirk ME, Maizels RM. Secretory acetylcholinesterases from Brugia malayi adult and microfilarial parasites. Molecular and biochemical parasitology 1987. link90078-8)